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Abstract A search for sequences homologous to the neurotensin 
receptor cDNA in a rat hypothalamic library has identified a 
novel neurotensin receptor (NTR-2). The 1539 bp cDNA encodes 
a 416 amino acid protein and shows highest homology to the 
previously cloned neurotensin receptor (NTR-I) (64% homology 
and 43% identity). Binding and pharmacological studies 
demonstrate that NTR-2 expressed in COS cells recognizes 
neurotensin (NT) with high affinity as well as several other 
agonists and antagonists. However, a fundamental difference was 
found; unlike NTR-1, NTR-2 recognizes, with high affinity, 
levocabastine, a histamine HI  receptor antagonist previously 
shown to compete with NT for low-affinity binding sites in brain. 
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study comparing the distributions of NTR and NTR tran- 
scripts in rat brain strongly suggested the existence of another 
NTR [24,25]. NTR transcripts are detected in several regions 
of the brain, but not in the subfornical organ, though NT 
binding sites were clearly associated with the cell bodies in 
this region [24]. These findings prompted us to undertake a 
search for other NTRs using a strategy based on sequence 
homology with the known NTR.  We describe here the mole- 
cular cloning of a novel NTR sharing 64% homology with the 
previously described receptor. We also report on the binding 
and pharmacological properties of this receptor expressed in 
COS cells. 
2. Materials and methods 
I. Introduction 
Neurotensin (NT) is a tridecapeptide involved in intercellu- 
lar communication i the central nervous system and periph- 
eral organs [1]. In the brain, NT acts as a neurotransmitter/ 
neuromodulator [2,3]. In particular, it modulates dopamine 
transmission in the nigrostrial and mesolimbic pathways 
[4,5]. Additionally, NT  plays a role in nociception, hypother- 
mia, control of pituitary hormone secretion and muscle re- 
laxation [6]. In adult rat brain, NT binds at two distinct sites 
distinguishable by (i) their sensitivity to levocabastine, a his- 
tamine H1 receptor antagonist and (ii) their differential affi- 
nity to neurotensin [7]. The levocabastin-sensitive NTR ap- 
pears after birth and exhibits a distribution in the brain 
different from the high-affinity NTR [8]. 
High-affinity levocabastine-insensitive NTR has been 
cloned from rat [9] and human [10,11]. This receptor repre- 
sents less than 30% of the NT  binding sites in the rat adult 
brain; and is found mainly in tile substantia nigra and the 
ventral tegmental area. The cloned rat NTR is a 424 amino 
acid protein that belongs to the G-protein-coupled superfam- 
ily of receptors. The biochemical and pharmacological proper- 
ties of this receptor have been extensively studied (for a review 
see [6]). It has been shown that upon activation the receptor 
modulates intracellular levels of cGMP [12], cAMP [13,14] 
and inositol phosphates [15-19]. The recently discovered 
non-peptide NT antagonist, SR 48692A inhibits the binding 
of NT  to the cloned receptor [20]. However, a recent study 
shows that in mouse and rat, NT-induced hypothermia nd 
analgesia re insensitive to SR48692 [21], suggesting that NT  
can act through different receptor subtypes. SR48692 has also 
been shown to differentially affect NT-induced behavior and 
changes in dopaminergic transmission [22,23]. Besides phar- 
macological arguments in favor of NTR subtypes, a recent 
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2.1. Drugs and peptides 
a25I-labeled [Tyr3]neurotensin and unlabeled neurotensin were pur- 
chased from NEN and Sigma, respectively. Dulbecco's modified es- 
sential medium (DMEM), fetal calf serum (FCS) and phosphate-buf- 
fered saline (PBS) were from Gibco (Paisley, UK). Bovine serum 
albumin (BSA), phenylmethylsulfonyl fluoride (PMSF) and 1,10-phe- 
nanthroline were from Sigma (St. Louis, MO). A selective, non-pep- 
tide antagonist SR 48692 was synthesized at Sanofi Recherche, Mont- 
pellier, France [20]. The anti-histamine agent, levocabastine, was 
obtained from Janssen Pharmaceutica (Geel, Belgium). 
2.2. RNA extraction and analysis 
Total RNA was extracted from rat hypothalamus using the acid 
guanidinium isothiocyanate phenol chloroform method [26]. Poly(A) 
containing RNA was isolated from total RNA by oligo(dT)-cellulose 
chromatography as described by Aviv and Leder [27]. RNA was size- 
fractionated by electrophoresis on 1% agarose/formaldehyde gelsthen 
blotted to nitrocellulose membranes [28]. Hybridization with a 32p_ 
labeled NTR cDNA was performed under low stringency conditions. 
2.3. eDNA library construction and DNA sequencing 
The cDNA library was constructed using the primer-adapter p o- 
cedure [29] and the pT3-T7 vector (Pharmacia). Nucleotide DNA 
sequences were determined by the dideoxy method of Sanger et al. 
[301. 
2.4. Transfection of COS cells and binding experiments 
The pharmacological characterization was performed using COS-3 
cells transfected with pSVL-NTR2 recombinant vector. 3 days after 
transfection, cell monolayers in 6-well plates were washed twice with 
50 mM Tris-HCl pH 7.5, 0.1% BSA, 0.1% NAN3, 1 mM 1,10-phenan- 
throline (binding buffer) before the binding of radioligand. 
Saturation experiments were performed in 1 ml of binding buffer 
containing 12~I-neurotensin over the range from 0.05 to 14.5 nM. 
After 1 h incubation at room temperature, the medium was aspirated 
and cell monolayers were washed twice with incubation buffer. Final- 
ly, cells were solubilized with 1 ml of 1 N NaOH and bound radio- 
activity was evaluated. Non-specific binding was defined as binding in 
the presence of a 500-fold excess of unlabeled ligand and under these 
experimental conditions was less than 1% of the total counts. 
Displacement experiments were conducted in an analogous manner 
using 0.2 nM 125I-neurotensin asradioligand. Neurotensin, neurome- 
din N, SR 48692 and levocabastine were used as competitors. 
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Binding data derived from saturation and competition experiments 
were analysed by using the computerized nonlinear curve-fitting soft- 
ware (Prim, GraphPad, San Diego, CA). 
3. Results 
3.1. Cloning and sequencing of protein related to the NT 
receptor 
Data from pharmacological studies consistently suggest 
that more than one neurotensin receptor might exist. Based 
on the assumption that NTR subtypes could be structurally 
related, we screened by homology a cDNA library made from 
rat hypothalamus. Approximately half a million recombinant 
bacteria were plated at high density on filters. Hybridization 
under low stringency conditions with a labeled rat NTR 
eDNA probe yielded several positive clones which were sub- 
sequently isolated. Systematic DNA sequencing analysis 
showed that only one of them shared substantial homology 
with the NTR cDNA. This 1539 bp long eDNA contained a 
large open-reading frame encoding a 416 amino acid protein. 
The putative NTR-2 protein, which shows 43% identity and 
64% homology with the NTR-1, has the structural features of 
a G-protein-coupled receptor (Fig. 1). Interestingly, although 
the lengths of both proteins are similar, the new receptor has a 
shorter N-terminal extracellular region, and a longer cytoplas- 
mic loop between the fifth and sixth putative transmembrane 
regions. It should also be noted that the cytoplasmic C-ter- 
minal region shows the lowest homology to NTR-1. 
3.2. Pharmacological characterization of cloned receptor 
We have examined the binding properties of NT to the new 
receptor expressed in COS-3 cells after transfection of the 
cloned cDNA. This receptor is able to bind 125I-neurotensin 
in a specific and saturable manner. Radiolabeled NT did not 
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Fig. 1. Alignment of the rNTR-2 to the rNTR-1. The complete 
rNTR-2 and rNTR-1 sequences are compared; gaps for alignment 
are indicated by dots and identical residues indicated by vertical 
lines. The solid lines above the sequences indicate the proposed 
transmembrane domains. 
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Fig. 2. (a) Saturation isotherm and Scatchard plot (inset) of the spe- 
cific binding of 12~I-labeled [monoiodo-Tyr3]neurotensin to COS-7 
cells transfected with the rNTR-2 eDNA. Each point represents he 
mean of triplicates. (b) Inhibition of 12~I-labeled [monoiodo- 
TyrZ]neurotensin b ding to COS-7 cells transfected with the rNTR- 
2 eDNA by unlabeled neurotensin (I), neuromedin N (©), SR 
48692 (v) and levocabastine (v). Each point represents he mean 
of triplicates. 
bind to untransfected cells, or to cells transfected with the 
vector DNA alone (not shown). Scatchard plot analysis of 
12'~'I-neurotensin binding (Fig. 2a) showed a single high-affinity 
population of receptors with a dissociation constant (Kd) of 
3.7 +-0.2 nM and a binding capacity (B .... ) of 180000 + 3000 
sites/cell. Fig. 2b shows competition curves of various ligands 
with labeled neurotensin. Agonists and antagonists competed 
for the binding of 125I-neurotensin with an order of potency 
similar to that for the NTR-1 previously described with the 
exception of the high affinity of levocabastine [10]. Neuroten- 
sin is the most potent competitor, with an apparent half-max- 
imal inhibiting concentration (ICs0) of 0.77 nM, followed by 
neuromedin N, ICs0 5.1 nM, and levocabastine, ICs0 10.0 nM. 
The recently described non-peptide antagonist, SR 48692, 
showed an ICs0 of 22.5 nM. 
3.3. mRNA tissue distribution 
The tissue distribution of NTR-2 mRNA was examined by 
northern blot analysis. As shown Fig. 3, poly(A) containing 
RNA from cortex and hypothalamus gave a strong signal 
when hybridized with labeled NTR-2 cDNA. Fainter signals 
were also obtained with RNA from heart and intestine. Two 
transcripts were systematically detected, with sizes of 1.6 and 
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Fig. 3. Northern blot analysis. Northern blot analyses were con- 
ducted using 10 gg of poly(A) RNA per lane and employing as la- 
beled probes cDNAs encoding NTR-2 or actin. 
1.4 kb. The shorter transcript is a splice variant encoding a
C-truncated receptor (results not shown). 
No transcript was detected in pituitary gland, spleen and 
kidney even using RT-PCR analysis. 
4. Discussion 
The discovery, almost a decade ago, of levocabastine-sensi- 
tive NT sites in rat [8] suggested the existence of NTR sub- 
types. The recent molecular cloning of a neurotensin receptor 
in rat [9] and human [10,11] (NTR-1), and the discovery of 
selective non-peptide antagonists of the NTR [20] have pro- 
vided further support for the existence of receptor subtypes. 
SR48692, for example, inhibits NT binding to NTR-1 but 
only antagonizes some of the effects of NT in vivo [21], sug- 
gesting that some of these effects might be mediated through 
an SR 48692-insensitive NTR. In addition, recent findings 
using a combination of high resolution in situ techniques dem- 
onstrated that NTR could be encoded by different mRNAs 
[24]. These observations constitute vidence for different ypes 
of NTR and prompted us to search for homologous receptors. 
We have identified a novel NTR (NTR-2) from rat hypotha- 
lamus which shares structural homologies (43% identity and 
64% similarity) with NTR-1. Interestingly, the lowest homo- 
logies between NTR-1 and NTR-2 are in their third cytoplas- 
mic loops and C-terminal domains, two regions bearing cou- 
pling specificity to G-protein. Binding studies show that the 
affinity of NT for NTR-2 is slightly lower than for NTR-1 
and that, importantly, levocabastine can efficiently compete 
with NT for occupancy of this site. 
NTR-2 seems to correspond to the levocabastine-sensitive 
NT site previously described [7]. NTR-2 transcripts are abun- 
dant in cortex and hypothalamus (Fig. 3) (100 more than 
NTR-1 mRNA), and absent in pituitary gland and brain em- 
bryos (results not shown). NTR-2 transcripts are also found 
in heart and gut, suggesting a possible implication of a NT/ 
NTR-2 pathway in muscle function. However, the functions 
of NTR-2 are presently unknown. Until now, levocabastine- 
sensitive NT binding sites have been considered as recognition 
sites for NT, devoid of signaling activity and hence named 
acceptor sites [31]. It will be surprising, considering the G- 
protein-coupled receptor structure of NTR-2, if this receptor 
does not signal to the cells. Nonetheless, the molecular cloning 
of NTR-2 will allow the testing of this assumption, and bio- 
chemical and pharmacological studies of NTR-2 which will 
certainly shed light on the biology of this receptor. 
In conclusion, it must be pointed out that the sensitivity of 
NTR-2 to SR48692 makes its implication in SR-insensitive 
NT-induced effects such as hypothermia nd analgesia un- 
likely, and so suggests other(s) NTR subtype(s). 
Finally, the availability of rat NTR-2 cDNA probe will 
enable us to answer the important question of the existence 
of an homologous receptor in man. 
References 
[1] Carraway, R. and Leeman, S.E. (1973) J. Biol. Chem. 24, 6854- 
6861. 
[2] Carraway, R., Ruane, S.E. and Hye-Ryeong, K. (1982) Peptides 
3, 115-123. 
[3] Mai, J.K., Triepel, J. and Metz, J. (1987) Neuroscience 22, 499 
524. 
[4] Nemeroff, C.B. (1986) Psychoneuroendocrinology 11, 15-37. 
[5] Kitabgi, P. (1989) Neurochem. Int. 14, 111-119. 
[6] Vincent, J.P. (1995) Cell. Mol. Neurobiol. 15, 501 512. 
[7] Schotte, A., Leysen, J.E. and Laduron, P.M. (1986) Naunyn- 
Schmiedeberg's Arch. Pharmacol. 333, 400~,05. 
[8] Schotte, A. and Laduron, P.M. (1987) Brain Res. 408, 326328. 
[9] Tanaka, K., Masu, M. and Nakanishi, S. (1990) Neuron 4, 847 
854. 
[10] Vita, N., Laurent, P., Lefort, S., Chalon, P., Dumont, X., 
Kaghad, M., Gully, D., Le Fur, G., Ferrara, P. and Caput, D. 
(1993) FEBS Lett. 317, 139 142. 
[11] Watson, M., Isackson, P.J., Makker, M., Yamada, M.S., Yama- 
da, M., Cusack, B. and Richelson, E. (1993) Mayo Clin. Proc. 68, 
1043-1048. 
[12] Amar, S., Mazella, J., Checler, F., Kitabgi, P. and Vincent, J.P. 
(1985) Biochem. Biophys. Res. Commun. 129, 117-125. 
[13] Bozou, J.C., Rochet, N., Magnaldo, I., Vincent, J.P. and Kitabgi, 
P. (1989) Biochem. J 264, 871 878. 
[14] Yamada, M., Watson, M.A. and Richelson, E. (1993) Eur. J. 
Pharmacol. 244, 99-101. 
[15] Watson, M.A., Yamada, M., Cusack, B., Veverka, K., Bolden- 
Watson, C. and Richelson, E. (1992) J. Neurochem. 59, 1967 
1970. 
[16] Oury-Donat, F., Thurneyssen, O., Gonalons, N., Forgez, P., 
Gully, D., Le Fur, G. and Soubri6, Ph. (1995) Br. J. Pharmacol. 
116, 1899-1905. 
[17] Hermans, E., Maloteaux, J.M. and Octave, J.N. (1994) Mol. 
Brain Res. 15, 332-338. 
[18] Chabry, J., Labbe-Jullie, C., Gully, D., Kitabgi, P., Vincent, J.P. 
and Mazella, J. (1994) J. Neurochem. 63, 19~7. 
[19] Hermans, E., Octave, J.N. and Maloteaux, J.M. (1996) Mol. 
Pharmacol. 49, 365-372. 
[20] Gully, D., Canton, M., Boigegrain, R., Jeanjean, F., Molimard, 
J.C., Poncelet, M., Gueudet, Ch., Heaulme, M., Leyris, R., 
Brouard, A., Pelaprat, D., Labb6-Julli6, C., Mazella, J., Soubri6, 
Ph., Maffrand, J.P., Rost+ne, W., Kitabgi, P. and Le Fur, G. 
(1993) Proc. Natl. Acad. Sci. USA 90, 65 69. 
[21] Dubuc, I., Costentin, J., Terranova, J.P., Barnouin, M.C., Sou- 
94 
brie, P., Le Fur, G., Rostene, W. and Kitabgi, P. (1994) Br. J. 
Pharmacol. 112, 35~354. 
[22] Poncelet, M., Gueudet, C., Gully, D., Soubrie, P. and Le Fur, G. 
(1994) Naunyn-Schmiedeberg's Arch. Pharmacol. 349, 57-60. 
[23] Steinberg, R., Brun, P., Fournier, M., Souilhac, J., Rodier, D., 
Mons, G., Terranova, J.P., Le Fur, G. and Soubrie, P. (1994) 
Neuroscience 59, 921-929. 
[24] Nicot, A., Rost~ne, W. and Berod, A. (1994) J. Cornp. Neurol. 
341,407~t09. 
[25] Le, F., Cusack, B. and Richelson, E. (1996) Trends Pharmacol. 
Sci. 17, 1-3. 
[26] Chomczynski, P. and Sacchi, N. (1987) Anal. Biochem. 162, 156 
159. 
P. Chalon et al./FEBS Letters 386 (1996) 91-94 
[27] Aviv, H. and Leder, P. (1972) Proc. Natl. Acad. Sci. USA 69, 
1408 1411. 
[28] Sambrook, J., Fritsch, E. and Maniatis, T. (1989) Cold Spring 
Harbor Laboratory Press, Cold Spring Harbor, NY. 
[29] Caput, D., Beutler, B., Hartog, K., Thayer, R., Brown-Schimer, 
S. and Cerami, A. (1986) Proc. Natl. Acad. Sci. USA 83, 1670- 
1674. 
[30] Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc. Natl. 
Acad. Sci. USA 74, 5463-5467. 
[31] Schotte, A., Leysen, J.E. and Laduron, P.M. (1986) Naunyn 
Schmiedeberg's Arch. Pharmacol. 333, 400M05. 
